We recently published Market on Mute? Not for These 10 Stocks With Surprising Gains. Hims & Hers Health, Inc. (NYSE:HIMS) is ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month to end a short-lived partnership to sell its Wegovy weight-loss drug ...

Hims & Hers Health Inc. board members and executives failed to tell shareholders that its Novo Nordisk A/S Wegovy ...

Big Pharma hates the telehealth startup. Meme-stock day traders love it. Why CEO Andrew Dudum won’t stop selling GLP-1s, no ...

The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

Hims & Hers Health, Inc. (NYSE:HIMS) is among the 13 Best Booming Stocks to Buy Now. On July 9, the digital health and ...

HIMS rebounds on GLP-1 growth and rising earnings estimates, while DXC slumps amid falling sales and eroding investor ...

We came across a bearish thesis on Hims & Hers on FJ Research’s Substack. As of 3ʳᵈ July, Hims & Hers’s share was trading at ...

The market for generic GLP-1 weight loss drugs in Canada is set to open up, and Hims & Hers is ready to jump in.  | Novo ...

Wall Street’s main indices finished in the green but with lackluster gains, with the Nasdaq rising 0.27 percent, the S&P 500 ...

From a receding hairline to thinning crown and balding, hair loss can be a difficult personal experience for many men as they ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...